Aspirin Underused in Secondary Prevention of Cardiovascular Disease
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
THURSDAY, Aug. 24, 2023 -- Aspirin is underused in secondary prevention of cardiovascular disease (CVD), according to a study published online Aug. 22 in the Journal of the American Medical Association.
Sang Gune K. Yoo, M.D., from Washington University in St. Louis, and colleagues reported and assessed aspirin use for secondary prevention of CVD in a cross-sectional analysis using data from 51 low-, middle-, and high-income countries. The overall pooled sample included 124,505 individuals aged 40 to 69 years.
The researchers found that 8.1 percent of the sample had a self-reported history of CVD. Aspirin use for secondary prevention among individuals with a history of CVD was 40.3 percent in the overall pooled sample. By income group, the estimates were 16.6, 24.5, 51.1, and 65.0 percent in low-, lower-middle, upper-middle, and high-income countries, respectively.
"In order to create interventions, we have to understand what is actually going on, which is what we're trying to establish in this study," Yoo said in a statement. "Then we can start to think about how to develop strategies to increase evidence-based aspirin use in order to save lives."
Two authors disclosed ties to the pharmaceutical industry; one author reported that their employer has a patent and license, and a second author reported having a patent pending.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2023
Read this next
Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM
FRIDAY, May 31, 2024 -- For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from...
DNA Methylation-Based Epigenetic Age Mediates Link Between LE8 Score, CVD
WEDNESDAY, May 29, 2024 -- The associations between Life's Essential 8 (LE8) and cardiovascular health are mediated by DNA methylation-based epigenetic age, according to a study...
Semaglutide Boosts Kidney Outcomes With Obesity + Cardiovascular Disease
TUESDAY, May 28, 2024 -- Once-weekly subcutaneous semaglutide shows a benefit for kidney outcomes in people with overweight or obesity and established cardiovascular disease...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.